Antitumor immunity as the basis for durable disease-free treatment-free survival in patients with metastatic urothelial cancer.

ABSTRACT: Cisplatin-based chemotherapy has been associated with durable disease control in a small subset of patients with metastatic urothelial cancer. However, the mechanistic basis for this phenomenon has remained elusive. Antitumor immunity may underlie these exceptional responders. In a phase II trial evaluating a phased schedule of gemcitabine and cisplatin followed by gemcitabine and cisplatin with ipilimumab for metastatic urothelial cancer, 4 of 36 patients achieved durable disease-free treatment-free survival (DDFTFS) and remain in remission over 5 years after enrolment on the study. We sought to identify the genomic and immunological mechanisms associated with functional cures of such patients. Whole exome sequencing was performed on pretreatment archival tumor tissue. Neoantigen predicti

SUBMITTER: Anker J 

PROVIDER: S-EPMC10445357 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature